NCT03355560View on ClinicalTrials.gov

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

January 1, 2024

Study Completion Date

July 31, 2024

Conditions
Head and Neck Cancer
Interventions
DRUG

Nivolumab

Nivolumab 480 mg IV infusion

Trial Locations (2)

45219

UC Health, Cincinnati

48201

Karmanos Cancer Institute, Detroit

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Trisha Wise-Draper

OTHER